Benitec Biopharma targets mid-2027 start for BB-301 pivotal trial in OPMD dysphagia

• Benitec outlined an FDA regulatory update for BB-301, keeping its pivotal OPMD study on track to start enrollment in mid-2027.
• FDA discussions continue on an open-label, single-arm pivotal design; the agency requested additional data, including the company’s OPMD natural history study.
• Final pivotal study design is expected to be confirmed in 1Q 2027, subject to FDA review of the added information.
• Interim Phase 1b/2a results have not yet been presented; they will be shown as a late-breaking poster at ESGCT on Oct. 27-30, 2026.
• The update signals continued regulatory alignment, supporting the planned transition from early-stage testing into a pivotal program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839296) on October 05, 2026, and is solely responsible for the information contained therein.